Tags

Type your tag names separated by a space and hit enter

A case of bullous pemphigoid associated with autoantibodies targeting antigenic sites other than the NC16a domain of BP180.
Clin Exp Dermatol. 2005 Sep; 30(5):503-5.CE

Abstract

Bullous pemphigoid (BP) is associated with autoantibodies to the 180-kDa BP antigen (BP180), and the antigenic site exists on noncollagenous 16a (NC16a) domain of BP180. We now report a male BP patient whose IgG autoantibodies did not react against the NC16a domain of BP180 by either immunoblotting or ELISA, whereas they did react with BP180 extracted from normal human keratinocytes. Anti-BP180 cicatricial pemphigoid was ruled out due to the lack of conjunctival mucosal involvement and the absence of scarring in the oral cavity. Our findings indicate that there is an antigenic reactive region other than NC16a on the extracellular domain of BP180. There have been few reports describing detailed clinical features of BP caused by autoantibodies targeting antigenic sites other than the NC16a domain. We conclude that it is difficult to differentiate their clinical features from those associated with autoantibodies targeting the NC16a domain of BP180.

Authors+Show Affiliations

Department of Dermatology, Surugadai Nihon University Hospital, Tokyo, Japan. yshino@med.nihon-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

16045678

Citation

Shinojima, Y, et al. "A Case of Bullous Pemphigoid Associated With Autoantibodies Targeting Antigenic Sites Other Than the NC16a Domain of BP180." Clinical and Experimental Dermatology, vol. 30, no. 5, 2005, pp. 503-5.
Shinojima Y, Ochiai T, Kawamura A, et al. A case of bullous pemphigoid associated with autoantibodies targeting antigenic sites other than the NC16a domain of BP180. Clin Exp Dermatol. 2005;30(5):503-5.
Shinojima, Y., Ochiai, T., Kawamura, A., Arakawa, H., Fukuda, K., & Hashimoto, T. (2005). A case of bullous pemphigoid associated with autoantibodies targeting antigenic sites other than the NC16a domain of BP180. Clinical and Experimental Dermatology, 30(5), 503-5.
Shinojima Y, et al. A Case of Bullous Pemphigoid Associated With Autoantibodies Targeting Antigenic Sites Other Than the NC16a Domain of BP180. Clin Exp Dermatol. 2005;30(5):503-5. PubMed PMID: 16045678.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A case of bullous pemphigoid associated with autoantibodies targeting antigenic sites other than the NC16a domain of BP180. AU - Shinojima,Y, AU - Ochiai,T, AU - Kawamura,A, AU - Arakawa,H, AU - Fukuda,K, AU - Hashimoto,T, PY - 2005/7/28/pubmed PY - 2005/12/13/medline PY - 2005/7/28/entrez SP - 503 EP - 5 JF - Clinical and experimental dermatology JO - Clin Exp Dermatol VL - 30 IS - 5 N2 - Bullous pemphigoid (BP) is associated with autoantibodies to the 180-kDa BP antigen (BP180), and the antigenic site exists on noncollagenous 16a (NC16a) domain of BP180. We now report a male BP patient whose IgG autoantibodies did not react against the NC16a domain of BP180 by either immunoblotting or ELISA, whereas they did react with BP180 extracted from normal human keratinocytes. Anti-BP180 cicatricial pemphigoid was ruled out due to the lack of conjunctival mucosal involvement and the absence of scarring in the oral cavity. Our findings indicate that there is an antigenic reactive region other than NC16a on the extracellular domain of BP180. There have been few reports describing detailed clinical features of BP caused by autoantibodies targeting antigenic sites other than the NC16a domain. We conclude that it is difficult to differentiate their clinical features from those associated with autoantibodies targeting the NC16a domain of BP180. SN - 0307-6938 UR - https://www.unboundmedicine.com/medline/citation/16045678/A_case_of_bullous_pemphigoid_associated_with_autoantibodies_targeting_antigenic_sites_other_than_the_NC16a_domain_of_BP180_ L2 - https://doi.org/10.1111/j.1365-2230.2005.01819.x DB - PRIME DP - Unbound Medicine ER -